Combined Modality Therapy: The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.Mechlorethamine: A biologic alkylating agent that exerts its cytotoxic effects by forming DNA ADDUCTS and DNA interstrand crosslinks, thereby inhibiting rapidly proliferating cells. The hydrochloride is an antineoplastic agent used to treat HODGKIN DISEASE and LYMPHOMA.Procarbazine: An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.Hodgkin Disease: A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.Lomustine: An alkylating agent of value against both hematologic malignancies and solid tumors.Vincristine: An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)Radiotherapy: The use of IONIZING RADIATION to treat malignant NEOPLASMS and some benign conditions.Antineoplastic Combined Chemotherapy Protocols: The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.Radiotherapy Dosage: The total amount of radiation absorbed by tissues as a result of radiotherapy.Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.Actuarial Analysis: The application of probability and statistical methods to calculate the risk of occurrence of any event, such as onset of illness, recurrent disease, hospitalization, disability, or death. It may include calculation of the anticipated money costs of such events and of the premiums necessary to provide for payment of such costs.Carcinoma, Small Cell: An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)Lung Neoplasms: Tumors or cancer of the LUNG.Radiotherapy, Adjuvant: Radiotherapy given to augment some other form of treatment such as surgery or chemotherapy. Adjuvant radiotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.Neoplasm Staging: Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.Cyclophosphamide: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.Survival Analysis: A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.Doxorubicin: Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.Prognosis: A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.Cisplatin: An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.Chemotherapy, Adjuvant: Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Clinical Trials as Topic: Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.Survival Rate: The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.Adenocarcinoma: A malignant epithelial tumor with a glandular organization.Disease-Free Survival: Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.Carcinoma, Non-Small-Cell Lung: A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.Follow-Up Studies: Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.Diagnostic Imaging: Any visual display of structural or functional patterns of organs or tissues for diagnostic evaluation. It includes measuring physiologic and metabolic responses to physical and chemical stimuli, as well as ultramicroscopy.Magnetic Resonance Imaging: Non-invasive method of demonstrating internal anatomy based on the principle that atomic nuclei in a strong magnetic field absorb pulses of radiofrequency energy and emit them as radiowaves which can be reconstructed into computerized images. The concept includes proton spin tomographic techniques.Tomography, X-Ray Computed: Tomography using x-ray transmission and a computer algorithm to reconstruct the image.

*  The Use of Chemotherapy Plus Radiotherapy Plus Azidothymidine in Patients With AIDS-Related Lymph Node Cancer - Full Text View ...
Drug Therapy, Combination. Combined Modality Therapy. Acquired Immunodeficiency Syndrome. Zidovudine. Brain Neoplasms. ... Radiation begins on day 1 of therapy. Patients receive dexamethasone orally (PO) or by intravenous injection (IV) on days 1-10 ... AZT while awake starts on day 1 of therapy and continues for 52 weeks. Patients are reevaluated with computerized tomography ( ... Since the underlying immunodeficiency state is not affected by therapy directed against the lymphoma, patients are still prone ...
*  Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer - Full Text View -...
Experimental: CMT with Radiation Therapy All patients will receive combined modality therapy (CMT) with 2 cycles of cisplatin ... Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer. This study has been ... Phase II Trial of Combined Modality Therapy Plus Cetuximab in HIV-Associated Anal Carcinoma. ... Radiation: radiation therapy Irradiation to tumor site and inguinal nodes beginning on cycle 1, Day 1 cisplatin/5-FU (minimum ...
*  Docetaxel and Radiation as Combined-Modality Therapy | Cancer Network | The Oncology Journal
Combined-modality approaches for the treatment of non-small-cell lung cancer (NSCLC), head and neck cancer, and esophageal ... combined-modality therapy.. Background. The taxanes are a class of antineoplastic agents, derived from plants, that. have ... Mauer AM, Haraf DC, Ferguson MK, et al: Docetaxel-based combined modality. therapy for locally advanced carcinoma of the ... have included single modalities such as surgery, radiation, or chemotherapy.. Combined modality approaches offer a theoretical ...
*  Combined-Modality Therapy for Head and Neck Cancer | Cancer Network | The Oncology Journal
... when combined with radiotherapy and/or surgery in the treatment of patients with head and neck cancer, appears to be most ... This paper presents an overview of the results of randomized trials of combined-modality therapy for advanced head and neck ... Lo TC, Wiley AL, Jr., Ansfield FJ, et al: Combined radiation therapy and 5-fluorouracil for advanced squamous cell carcinoma of ... Adelstein DJ, Sharan VM, Earle AS, et al: Simultaneous versus sequential combined technique therapy for squamous cell head and ...
*  Combined Modality Therapy of Childhood Non-Hodgkin's Lymphoma | Springer for Research & Development
... has improved in the recent past through the systematic application of intensive therapy employing involved field radiation plus ... Murphy S.B. (1978) Combined Modality Therapy of Childhood Non-Hodgkin's Lymphoma. In: Mathé G., Seligmann M., Tubiana M. (eds) ... A comprehensive review of combined modality therapy of NHL in childhood has been published recently [9]. Table 1, which ... A comparative study of two modalities of therapy. Cancer 37, 123- 134(1976)PubMedCrossRefGoogle Scholar ...
*  A Phase II Study of Combine Modality Therapy in Locally Advanced Pancreatic Cancer - Full Text View -
A Phase II Study of Combine Modality Therapy in Locally Advanced Pancreatic Cancer. The safety and scientific validity of this ... Because patients with immune deficiency are at increased risk of lethal infections when treated with marrow-suppressive therapy ... Appropriate studies will be undertaken in patients receiving combination anti-retroviral therapy when indicated. ... HIV-positive patients receiving combination anti-retroviral therapy are excluded from the study because of possible ...
*  IJMS | Free Full-Text | Biomarkers of Treatment Toxicity in Combined-Modality Cancer Therapies with Radiation and Systemic...
In view of the complexity of biological responses to cancer therapy, this communication reports on a ... Organ toxicity in cancer therapy is likely caused by an underlying disposition for given pathophysiological mechanisms in the ... Ree AH, Meltzer S, Flatmark K, Dueland S, Kalanxhi E. Biomarkers of Treatment Toxicity in Combined-Modality Cancer Therapies ... Biomarkers of Treatment Toxicity in Combined-Modality Cancer Therapies with Radiation and Systemic Drugs: Study Design, ...
*  Health Library
Combined Modality Therapy (CMT) TOP. CMT is a term gaining popularity and meaning several treatments at once or in succession. ... Radiation Therapy. Radiation therapy uses radiation to kill cancer cells and shrink tumors. Radiation is most often ... Although it has not been shown that chemo- and radiation therapy at the same time are better than radiation therapy alone in ... The physical exam combined with all of your test results, will help to determine the stage of cancer you have. Staging is used ...
*  Pancreatic Cancer | Doctors Hospital
Combined Modality Therapy. Most times, pancreatic cancer is discovered at an advanced stage. Surgery may not be appropriate in ... Radiation Therapy. This is the use of radiation to kill cancer cells and shrink tumors. Radiation therapy may be: *External- ... The physical exam combined with all of your test results, will help to determine the stage of cancer you have. Staging is used ... Biological Therapy. The use of medications or substances made by the body. They can increase or restore the body's natural ...
*  A Study on the Effect of Chemotherapy Combined With Anti-HIV Drugs in HIV-Positive Patients - Full Text View - ClinicalTrials...
Drug Therapy, Combination. Granulocyte Colony-Stimulating Factor. Combined Modality Therapy. Antineoplastic Agents. Lymph Nodes ... Effect of Cytoreductive Chemotherapy Combined With Highly Active Antiretroviral Therapy on Lymph Node HIV DNA in HIV-Infected ... A Study on the Effect of Chemotherapy Combined With Anti-HIV Drugs in HIV-Positive Patients. This study has been completed. ... Antiretroviral therapy (ART) plus cyclophosphamide (CTX) to diminish HIV DNA in lymphoid tissue. 8th Conf Retro and Opportun ...
*  A Study of Chemotherapy Plus ddI or ddC in the Treatment of AIDS-Related Kaposi's Sarcoma - Full Text View -...
Drug Therapy, Combination. Combined Modality Therapy. Acquired Immunodeficiency Syndrome. Antineoplastic Agents. Antineoplastic ... On the average, patients receive 12-44 weeks of combined chemotherapy and antiretroviral therapy. If vincristine is deleted ...
*  Chemotherapy and Azidothymidine, With or Without Radiotherapy, for High Grade Lymphoma in AIDS-Risk Group Members - Full Text...
Drug Therapy, Combination. Combined Modality Therapy. Acquired Immunodeficiency Syndrome. Antineoplastic Agents, Combined. ... Investigational therapies, except ganciclovir therapy for sight- or life-threatening cytomegalovirus infection. ... Antiretroviral therapy prior to diagnosis of lymphoma.. Patients must demonstrate the following clinical and laboratory ... Ganciclovir therapy for sight- or life-threatening Cytomegalovirus infection.. *Zidovudine and methotrexate may be resumed ...
*  Meetings - The ASCO Post
Despite Challenges, Combined-modality Therapy Warranted for Locally Recurrent Colorectal Cancer. Encouraging outcomes have been ... achieved with a combined-modality treatment approach for patients with locally recurrent colorectal cancer in both curative and ... Surprisingly, less may be more when it comes to radiation therapy with concurrent chemotherapy for patients with stage III non- ... The use of intensity-modulated radiation therapy (IMRT) is associated with fewer acute and late toxic effects than is three- ...
*  Volume 1, Issue 4A, September 2006: Locked-In Syndrome | National Rehabilitation Information Center
Combined Modality Therapy. *Communication/Devices. *Consciousness Disorders. *Early Intervention. *Ethics (clinical). *Eye ... During the course of therapy, which started more than five years after onset and lasted for as much as 11 years, the client ... Leon-Carrion, J., Van Eeckhout, P., & Dominguez-Morales, M.R. (2005). The locked-in syndrome: a challenge for therapy. Acta ... This case study suggests that intrathecal baclofen pump therapy might improve motor function in select patients with locked-in ...
*  Volume 7, Issue 1, Aging with Disabilities | National Rehabilitation Information Center
Combined Modality Therapy. *Communication Disabilities/Skills. *Community Health/Living/Networks/Resources/Services ... Barnhart, R.C., & Connolly, B. (2007). Aging and Down syndrome: Implications for physical therapy. Physical therapy, 87(10), ... ABSTRACT: Journal issue with articles on topics related to physical therapy (PT) and occupational therapy (OT) for older adults ... Hormone replacement therapy has both greater potential benefit and greater potential risks. Review of these issues makes ...
*  Short Neoadjuvant Hemithoracic IMRT for MPM
Suitable for combined modality therapy - Informed consent Exclusion Criteria: - Distant metastatic disease ... Time Frame: After completion of therapy: every 4 wks for 3 mos, then every 6 wks for 6 mos, then every 2 mos for 12 mos, then ... Radiation therapy (RT) dramatically reduces the risk of tumour recurrence within the irradiated area (>90%). But patients ... Good pulmonary function precluding radiation therapy (FEV>1 L or >40% predicted or DLCO >45% predicted) ...
*  Can exercise ameliorate treatment toxicity during the initial phase of testosterone deprivation in prostate cancer patients? Is...
There has been substantial increase in use of androgen deprivation therapy as adjuvant management of prostate cancer. However, ... Combined Modality Therapy. Cross-Over Studies. Exercise Therapy / methods*. Humans. Male. Prostatic Neoplasms / drug therapy*, ... A phase III clinical trial of exercise modalities on treatment side-effects in men receiving therapy for prostate cancerBMC ... Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for ...
*  Treatment of refractory melasma with the MedLite C6 Q-switched Nd:YAG laser and alpha arbutin: a prospective study.
Combined Modality Therapy. Female. Humans. Laser Therapy, Low-Level* / adverse effects. Lasers, Solid-State / adverse effects, ... Previous Document: Journal of Cosmetic and Laser Therapy. Editorial.. Next Document: Treatment of infantile hemangioma with ... CONCLUSION: Combination therapy with the MedLite C6 and 7% alpha arbutin solution is an effective and well-tolerated treatment ... Title: Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology Volume: 12 ...
*  Treatment of hypertrophic scars using a long-pulsed dye laser with cryogen-spray cooling.
Cicatrix, Hypertrophic / ethnology, pathology, therapy*. Combined Modality Therapy. Cryotherapy* / adverse effects. Erythema / ... 8210149 - Radiation therapy as a cause of capsular contracture.. 19766399 - Comparison of efficacy of silicone gel, silicone ... Next Document: Treatment of congenital melanocytic nevi using the combined (normal-mode plus Q-switched) ruby laser.... ...
*  Tratamento da doença de Hailey-Hailey com toxina botulínica tipo A
Keywords : Botulinum toxin type A; Combined modality therapy; Pemphigus, benign familial. · abstract in Portuguese · text in ...
*  Michael L. J. Apuzzo - Wikipedia
"Combined Modality Therapy of Central Nervous System Tumors". ISBN 9783540006275. Hoh DJ, Liu CY, Pagnini PG, Yu C, Wang MY, ... Chained lightning: part III--Emerging technology, novel therapeutic strategies, and new energy modalities for radiosurgery. ... technology transfer and the implementation of advanced technologies to the therapy of brain diseases. In 1991, he was appointed ...
*  Precocious puberty - Wikipedia
"Intracranial choriocarcinoma causing precocious puberty and cured with combined modality therapy". Journal of Paediatrics and ...
*  Articles | Radiology Research | Henry Ford Health System - Detroit, MI
E. Karami and H. Soltanian-Zadeh: "Design and Implementation of Ultrasound Phased Arrays for Cancer Therapy." Presented at and ... H. Soltanian-Zadeh, J.P. Windham, D.J. Peck, and L. Emery: "Combining Cluster Analysis with Supervised Segmentation Methods for ... M. Siadat, H. Soltanian-Zadeh, F. Fotouhi, K. Elisevich, "Multi-modality Medical Image Database for Temporal Lobe Epilepsy," ... M. Mousavi and H. Soltanian-Zadeh: "A Combined Method for the Compression of Pathological Colored Images." Presented at and ...
*  Uni-Patch™ Heavy Duty Cold Packs : Balego & Associates Inc. -, Providing the Products You Want and the...
Exercise Treatment Tables Massage Therapy Orthopaedic Pillows Traction Range of Motion Back - Lumbar Care & Rehab Cushions: ... Healthcare Orthopedic Supports Compression Therapy Vascular Compression/Stimulation Sharps, Needles and Syringes Balego® Sport ... Cardiology Products Wound Care Incontinence Urology Training Biofeedback Physical Therapy Modalities Exercise and Balance ... Non-toxic and colorless gel filling combined with a latex free outer shell. Provides a safer product for the patient and ...

Abscopal effect: The abscopal effect is a phenomenon in the treatment of metastatic cancer where localized treatment of a tumor causes not only a shrinking of the treated tumor but also a shrinking of tumors in different compartments from the treated tumor. Initially associated with single-tumor, localized radiation therapy, the term has also come to encompass other types of localized treatments such as electroporation and intra-tumoral injection of therapeutics.ProcarbazineNodular lymphocyte predominant Hodgkin's lymphomaLow-dose chemotherapy: Low-dose chemotherapy is being studied/used in the treatment of cancer to avoid the side effects of conventional chemotherapy. Historically, oncologists have used the highest possible dose that the body can tolerate in order to kill as many cancer cells as possible.External beam radiotherapySmall-cell carcinomaTargeted therapy of lung cancer: Targeted therapy of lung cancer refers to using agents specifically designed to selectively target molecular pathways responsible for, or that substantially drive, the malignant phenotype of lung cancer cells, and as a consequence of this (relative) selectivity, cause fewer toxic effects on normal cells.ABCD rating: ABCD rating, also called the Jewett staging system or the Whitmore-Jewett staging system, is a staging system for prostate cancer that uses the letters A, B, C, and D.DoxorubicinLipoplatin: Lipoplatin (Liposomal cisplatin) is a nanoparticle of 110 nm average diameter composed of lipids and cisplatin. This new drug has successfully finished Phase I, Phase II and Phase III human clinical trials (2,3).Community-based clinical trial: Community-based clinical trials are clinical trials conducted directly through doctors and clinics rather than academic research facilities. They are designed to be administered through primary care physicians, community health centers and local outpatient facilities.Cancer survival rates: Cancer survival rates vary by the type of cancer, stage at diagnosis, treatment given and many other factors, including country. In general survival rates are improving, although more so for some cancers than others.Adenocarcinoma of the lung: Adenocarcinoma of the lung (pulmonary adenocarcinoma) is a common histological form of lung cancer that contains certain distinct malignant tissue architectural, cytological, or molecular features, including gland and/or duct formation and/or production of significant amounts of mucus.Clinical endpoint: In a clinical research trial, a clinical endpoint generally refers to occurrence of a disease, symptom, sign or laboratory abnormality that constitutes one of the target outcomes of the trial, but may also refer to any such disease or sign that strongly motivates the withdrawal of that individual or entity from the trial, then often termed humane (clinical) endpoint.PemetrexedHyperintensityDense artery sign: In medicine, the dense artery sign or hyperdense artery sign is a radiologic sign seen on computer tomography (CT) scans suggestive of early ischemic stroke. In earlier studies of medical imaging in patients with strokes, it was the earliest sign of ischemic stroke in a significant minority of cases.

(1/14907) Adenoviral gene transfer into the normal and injured spinal cord: enhanced transgene stability by combined administration of temperature-sensitive virus and transient immune blockade.

This study characterized gene transfer into both normal and injured adult rat dorsal spinal cord using first (E1-/E3-) or second (E1-/E2A125/E3-, temperature-sensitive; ts) generation of replication-defective adenoviral (Ad) vectors. A novel immunosuppressive regimen aimed at blocking CD4/CD45 lymphocytic receptors was tested for improving transgene persistence. In addition, the effect of gene transfer on nociception was also evaluated. Seven days after treatment, numerous LacZ-positive cells were observed after transfection with either viral vector. By 21 days after transfection, beta-galactosidase staining was reduced and suggestive of ongoing cytopathology in both Ad-treated groups, despite the fact that the immunogenicity of LacZ/Adts appeared less when compared with that elicited by the LacZ/Ad vector. In contrast, immunosuppressed animals showed a significant (P < or = 0.05) increase in the number of LacZ-positive cells not displaying cytopathology. In these animals, a concomitant reduction in numbers of macrophages/microglia and CD4 and CD8 lymphocytes was observed. Only animals that received LacZ/Adts and immunosuppression showed transgene expression after 60 days. Similar results were observed in animals in which the L4-L5 dorsal roots were lesioned before transfection. Gene transfer into the dorsal spinal cord did not affect nociception, independent of the adenovirus vector. These results indicate that immune blockade of the CD4/CD45 lymphocytic receptors enhanced transgene stability in adult animals with normal or injured spinal cords and that persistent transgene expression in the spinal cord does not interfere with normal neural function.  (+info)

(2/14907) Systemic administration of rIL-12 synergistically enhances the therapeutic effect of a TNF gene-transduced cancer vaccine.

Interleukin-12 (IL-12) is a potent antitumor cytokine, which induces and enhances the activity of natural killer (NK) cells, lymphokine activated killer (LAK) cells and cytotoxic T lymphocytes (CTL). IL-12 also stimulates IFN-gamma production from both T cells and NK cells. In this study, we transfected methylcholanthrene-induced fibrosarcoma (MCA-D) with TNF gene and investigated the therapeutic effect of TNF gene-transduced cancer vaccine and whether the vaccination effect is enhanced by systemic administration of recombinant IL-12 (rIL-12), in a murine model. TNF gene-transduced cancer vaccine or systemic administration of rIL-12 showed slight or moderate inhibition of pre-established tumor. However, simultaneous application of the vaccine and rIL-12 resulted in complete eradication. The cytotoxicity of CTL against parental tumor cells was enhanced with the combination of the vaccine and rIL-12, and IFN-gamma production from spleen cells also increased synergistically. Our findings show that synergistic enhancement of CTL activity and IFN-gamma production could play an important role in the antitumor effect of combination therapy using TNF gene-transduced cancer vaccine and rIL-12.  (+info)

(3/14907) Reirradiation combined with hyperthermia in recurrent breast cancer results in a worthwhile local palliation.

Both experimental and clinical research have shown that hyperthermia (HT) gives valuable additional effects when applied in combination with radiotherapy (RT). The purpose of this study was evaluation of results in patients with recurrent breast cancer, treated at the Daniel den Hoed Cancer Center (DHCC) with reirradiation (re-RT; eight fractions of 4 Gy twice weekly) combined with HT. All 134 patients for whom such treatment was planned were included in the analysis. The complete response rate in 119 patients with macroscopic tumour was 71%. Including the 15 patients with microscopic disease, the local control rate was 73%. The median duration of local control was 32 months, and toxicity was acceptable. The complete response (CR) rate was higher, and the toxicity was less with the later developed 433-MHz HT technique compared with the 2450-MHz technique used initially. With this relatively well-tolerated treatment, palliation by local tumour control of a worthwhile duration is achieved in the majority of patients. The technique used for hyperthermia appeared to influence the achieved results. The value of HT in addition to this re-RT schedule has been confirmed by a prospective randomized trial in a similar patient group. In The Netherlands, this combined treatment is offered as standard to patients with breast cancer recurring in previously irradiated areas.  (+info)

(4/14907) A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss.

The use of megestrol acetate in the treatment of weight loss in gastrointestinal cancer patients has been disappointing. The aim of the present study was to compare the combination of megestrol acetate and placebo with megestrol acetate and ibuprofen in the treatment of weight loss in such patients. At baseline, 4-6 weeks and 12 weeks, patients underwent measurements of anthropometry, concentrations of albumin and C-reactive protein and assessment of appetite, performance status and quality of life using EuroQol-EQ-5D and EORTC QLQ-C30. Thirty-eight and 35 patients (median weight loss 18%) were randomized to megestrol acetate/placebo or megestrol acetate/ibuprofen, respectively, for 12 weeks. Forty-six (63%) of patients failed to complete the 12-week assessment. Of those evaluable at 12 weeks, there was a decrease in weight (median 2.8 kg) in the megestrol acetate/placebo group compared with an increase (median 2.3 kg) in the megestrol acetate/ibuprofen group (P<0.001). There was also an improvement in the EuroQol-EQ-5D quality of life scores of the latter group (P<0.05). The combination of megestrol acetate/ibuprofen appeared to reverse weight loss and appeared to improve quality of life in patients with advanced gastrointestinal cancer. Further trials of this novel regimen in weight-losing patients with hormone-insensitive cancers are warranted.  (+info)

(5/14907) The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients.

We analysed 57 patients with non-myeloid malignancies who received a non-purged autologous PBSCT. All had similar mobilisation and conditioning regimens. A high prior chemotherapy score and the number of chemotherapy lines used (P = 0.015 and P = 0.01, respectively) were adverse predictors of CD34 cell yields. Lower CD34 values (P = 0.002) were seen in patients treated with potent stem cell toxins (BCNU, melphalan, CCNU and mustine), designated toxicity factor 4 agents (TF4). All patients infused with grafts containing CD34 cell doses between 1.0 and 2.0 x 10(6)/kg (range 1.25-1.90) engrafted by day 51. The only variable associated with slow platelet recovery was exposure to TF4 (P = 0.007). The majority of patients with CD34 >1.0 x 10(6)/kg achieved rapid and sustained engraftment and the only predictive factor of delayed recovery is prior exposure to stem cell toxins. Potential PBSCT candidates should if possible avoid first line and salvage chemotherapy containing TF4 drugs. We therefore advocate a minimum CD34 threshold of >1.0 x 10(6)/kg in patients without extensive prior chemoradiotherapy, and > or = 2.0 x 10(6)/kg in all other patients.  (+info)

(6/14907) Infectious complications in 126 patients treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation.

The effect of an extensive prophylactic antimicrobial regimen was prospectively assessed in 126 patients after high-dose chemotherapy and autologous PBSC. They received ciprofloxacin (500 mg/12 h), acyclovir (200 mg/6 h), and itraconazole (200 mg/12 h) orally until neutrophil recovery. Febrile patients received i.v. imipenem (500 mg/6 h) to which vancomycin and amikacin were added if fever persisted for 2-3 and 5 days, respectively. Amphotericin B lipid complex was further given on day 7 or 8 of fever. Median times for a neutrophil count of >0.5 x 10(9)/l and a platelet count of >20 x 10(9)/l were 9 and 11 days. Severe neutropenia (<0.1 x 10(9)/l) lasted for a median of 5 days in which 72% of febrile episodes and 50% of cases of bacteremia occurred. Gram-positive bacteria were isolated in 30 of 40 episodes of bacteremia, 25 of which were caused by Staphylococcus epidermidis. Clinical foci were the intravascular catheter in 35 cases, respiratory infection in 11, cellulitis in two, anal abscess in one, and neutropenic enterocolitis in one. The high incidence of febrile episodes (94%) and bacteremias (31%) may be due to the lack of efficacy of antimicrobial prophylaxis and the persistence of a 5-day period of severe neutropenia.  (+info)

(7/14907) Lymphomatoid granulomatosis following autologous stem cell transplantation.

Lymphomatoid granulomatosis (LYG) is a rare angio-destructive lymphoproliferative disorder (LPD) of uncertain etiology, with prominent pulmonary involvement. Recent studies indicate that LYG is an Epstein-Barr virus (EBV)-associated B cell LPD with large numbers of background reactive T lymphocytes (T cell-rich B cell lymphoma). Although the disease frequently, but not exclusively, occurs in various immunodeficiency states, it has not been reported in association with the transient immunosuppression following autologous bone marrow/peripheral stem cell transplantation (ABM/PSCT). We describe a patient who developed lymphomatoid granulomatosis of the lung approximately 2 weeks after high-dose chemotherapy and autologous peripheral stem cell transplantation for multiple myeloma. Although molecular studies showed no evidence of EBV genome in the biopsy material, the serologic profile with high IgM titers was suggestive of primary EBV infection. Complete radiologic remission occurred following reconstitution of the patient's immune response after a 2-week course of ganciclovir treatment. Despite the apparently low frequency of LPD (both LYG and EBV-associated post-transplant lymphoma) in the ABMT setting, we believe that it should be considered in the differential diagnosis of patients whose clinical course following ABMT is complicated by fevers, in the absence of an identifiable infectious process.  (+info)

(8/14907) Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer.

5-Fluorouracil (5-FU) is an effective enhancer of radiation therapy (RT) in head and neck cancers. Due to rapid, predominantly hepatic metabolism by dihydropyrimidine dehydrogenase (DPD) and suggested clinical benefit from prolonged drug exposure, 5-FU is commonly given by continuous infusion. Eniluracil is a novel DPD-inactivator designed to prolong the half-life of 5-FU and provide sustained plasma concentrations of 5-FU with oral dosing. We conducted a Phase I study of the safety and efficacy of eniluracil given with oral 5-FU in patients receiving concurrent RT for recurrent or advanced squamous cell carcinomas of the head and neck. Thirteen patients with recurrent, metastatic, or high-risk (defined as an expected 2-year survival rate of <10%) head and neck cancer were enrolled and treated with concomitant chemoradiotherapy on an every-other-week schedule. Eniluracil at a fixed dose [20 mg twice a day (BID)] was given for 7 consecutive days (days 1-7). 5-FU and RT were given on 5 consecutive days (days 2-6). One patient was treated with once-daily RT (2.0 Gy fractions). The remaining patients received hyperfractionated RT (1.5-Gy fractions BID). The initial dose of 5-FU was 2.5 mg/m2 given BID. Dose escalation in patient cohorts was scheduled at 2.5-mg/m2 increments, with intrapatient dose escalation permitted. Lymphocyte DPD activity and serum 5-FU and uracil concentrations were monitored during two cycles. DPD activity was completely or nearly completely inactivated in all patients. Sustained, presumed therapeutic concentrations of 5-FU were observed at a dose of 5.0 mg/m2 given BID. Cumulative dose-limiting myelosuppression (both neutropenia and thrombocytopenia) was observed during the fourth and fifth cycles following administration of 5.0 mg/m2 5-FU BID. One patient died of neutropenic sepsis during cycle 4. Other late cycle toxicities included diarrhea, fatigue, and mucositis. Grade 3 mucositis was observed in 4 patients, but no grade 4 mucositis or grade 3 or 4 dermatitis was observed. A second patient death occurred during cycle 1 of treatment. No specific cause of death was identified. The study was subsequently discontinued. Cumulative myelosupression was the significant dose-limiting toxicity of oral 5-FU given with the DPD-inactivator eniluracil on an every-other-week schedule. Clinical radiation sensitization was not observed, based on the absence of dose-limiting mucositis and dermatitis. Alternative dosing schedules need to be examined to determine the most appropriate use of eniluracil and 5-FU as radiation enhancers.  (+info)

  • radiotherapy
  • citation needed] His scientific career in neuro- and thoracic oncology started in 1988 and was marked by a zealous focus on evidence-based medicine through clinical and translational research, including a variety of areas such as endobronchial brachytherapy, radioimmunotherapy, stereotactic radiosurgery, fractionated stereotactic radiotherapy, image-guided and intensity-modulated radiotherapy, radioprotectors, radiosensitizers, altered fractionation, combination chemoradiotherapy as well as combining targeted agents with radiotherapy. (
  • He was named Director of Radiotherapy in the Cancer Therapy & Research Center, under the National Cancer Institute, where he led a team of professionals that achieved optimal results within the field. (
  • He was elected Head of the Radiotherapy department of the Cancer Therapy & Research Center every year between 1993 and 2007. (
  • clinical
  • In regard to investigation of causes and potential targets for therapy, the route used starts with data obtained from clinical observations, enters basic research, and, once convincing and independently confirmed results are obtained, proceeds with clinical research, involving appropriately designed trials on consenting human subjects, with the aim to test safety and efficiency of the therapeutic intervention method. (
  • As a mental health profession, art therapy is employed in many clinical and other settings with diverse populations. (
  • Art therapy can also be found in non-clinical settings, as well as in art studios and in creativity development workshops. (
  • Madolyn M. Liebing, Ph.D. (of Aspen Achievement then, and currently of Journey Wilderness) was the first clinical psychologist to integrate clinical therapy with wilderness programming. (
  • Additionally, most wilderness therapy programs have highly trained clinical staff either on the expedition or in active and ongoing consultation with the team. (
  • entities
  • The most successful targeted therapies are chemical entities that target or preferentially target a protein or enzyme that carries a mutation or other genetic alteration that is specific to cancer cells and not found in normal host tissue. (
  • tumor cells
  • The definitive experiments that showed that targeted therapy would reverse the malignant phenotype of tumor cells involved treating Her2/neu transformed cells with monoclonal antibodies in vitro and in vivo by Mark Greene's laboratory and reported from 1985. (
  • patients
  • Since the underlying immunodeficiency state is not affected by therapy directed against the lymphoma, patients are still prone to life-threatening opportunistic infections or relapse of lymphomatous disease within the CNS. (
  • Biomarkers are usually required to aid the selection of patients who will likely respond to a given targeted therapy. (
  • By exposing patients to interpersonal problems, therapy and group activities in an unfamiliar context away from home, wilderness therapy encourages the development of healthy self-esteem and social skills. (
  • In many patients with cancer, this condition does not develop until months or even years after therapy has concluded. (
  • Death is attributable to upper airway obstruction and suffocation in half of patients, and to a combination of complications of local and distant disease, or therapy, or both in the remainder. (
  • Biological
  • In view of the complexity of biological responses to cancer therapy, this communication reports on a "top-down" strategy, starting with the systematic assessment of adverse effects within a defined therapeutic context and proceeding to transcriptomic and proteomic analysis of relevant patient tissue samples and computational exploration of the resulting data, with the ultimate aim of utilizing information from functional connectivity networks in evaluation of patient safety in multimodal cancer therapy. (
  • medical
  • medical citation needed] Alternately, some programs are derived from a more ecopsychological perspective, according to the director of the wilderness therapy program at Naropa University, "through contemplative practice and the experiential outdoor classroom, students gain further self-awareness and the ability to respond to whatever arises in the moment. (
  • approach
  • The success of the Outward Bound outdoor education program in the 1940s inspired the approach taken by many current-day wilderness therapy programs, though some adopted a survivalist methodology. (
  • communication
  • The British Association of Art Therapists defines art therapy as "a form of psychotherapy that uses art media as its primary mode of expression and communication. (
  • various
  • Various definitions of the term "art therapy" exist. (
  • It was Mercieca's recovery and discoveries that led her to become trained in various skills, acquiring a Life and Business certificate in Coaching, before going on to learn the art of Neuro-Linguistic Programming, Time-Line Therapy, Hypnosis and Wholebrain Intelligence (she is also accredited with the relevant boards in America). (
  • major
  • One of the major differences between boot camps and wilderness therapy is the underlying philosophical assumptions (wilderness therapy being driven by the philosophy of experiential education and theories of psychology and boot camps being informed by a military model). (
  • development
  • citation needed] The New York Asylum and the San Francisco Agnew Asylum played an early role in the development of wilderness therapy, drawing upon the philosophies of Kurt Hahn. (
  • cells
  • This study examines whether this combination therapy can reduce the number of HIV-infected cells hidden in the lymph nodes and blood. (
  • Type
  • His report on Radium Therapy in Cancer, at the Memorial Hospital (1915-1916), which appeared in book form in 1917 was the most comprehensive work of its type published in the United States. (
  • term
  • Depending on the state, province, or country, the term "art therapist" may be reserved for those who are professionals trained in both art and therapy and hold a master or doctoral degree in art therapy or certification in art therapy obtained after a graduate degree in a related field. (
  • View
  • Many wilderness therapy programs avoid what they view as manipulations, contrived activities, psychological games, and contrived consequences. (
  • given
  • Organ toxicity in cancer therapy is likely caused by an underlying disposition for given pathophysiological mechanisms in the individual patient. (
  • help
  • The physical exam combined with all of your test results, will help to determine the stage of cancer you have. (
  • In Stella A. Stephney's book Art Therapy With Students At Risk: Fostering Resilience and Growth through Self-Expression, Stephney states that art therapy can be used to help at-risk children. (
  • field
  • Art therapists may have received advanced degrees in art therapy or in a related field such as psychology in which case they would have to obtain post-master's or post-doctorate certification as an art therapist. (
  • programs
  • Some programs which advertise as "wilderness therapy" are actually boot camps in a wilderness environment. (
  • These can sometimes be distinguished from other wilderness therapy by such programs promising behavior modification for troubled teens, but it is hard to tell just from the ads. (
  • Growth
  • By contrast, other inhibitions of growth-signals like those associated with receptor tyrosine kinases are referred to as targeted therapy. (
  • form
  • Another form of targeted therapy involves use of nanoengineered enzymes to bind to a tumor cell such that the body's natural cell degradation process can digest the cell, effectively eliminating it from the body. (